JP2012525410A5 - - Google Patents

Download PDF

Info

Publication number
JP2012525410A5
JP2012525410A5 JP2012508648A JP2012508648A JP2012525410A5 JP 2012525410 A5 JP2012525410 A5 JP 2012525410A5 JP 2012508648 A JP2012508648 A JP 2012508648A JP 2012508648 A JP2012508648 A JP 2012508648A JP 2012525410 A5 JP2012525410 A5 JP 2012525410A5
Authority
JP
Japan
Prior art keywords
antigen
combination
virus
mammal
combination according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012508648A
Other languages
English (en)
Japanese (ja)
Other versions
JP5690814B2 (ja
JP2012525410A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/032779 external-priority patent/WO2010129339A2/en
Publication of JP2012525410A publication Critical patent/JP2012525410A/ja
Publication of JP2012525410A5 publication Critical patent/JP2012525410A5/ja
Application granted granted Critical
Publication of JP5690814B2 publication Critical patent/JP5690814B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012508648A 2009-04-28 2010-04-28 抗原特異的な免疫応答を高めるための組成物及び方法 Expired - Fee Related JP5690814B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17341309P 2009-04-28 2009-04-28
US61/173,413 2009-04-28
PCT/US2010/032779 WO2010129339A2 (en) 2009-04-28 2010-04-28 Compositions and methods for enhancing antigen-specific immune responses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014193613A Division JP2015017117A (ja) 2009-04-28 2014-09-24 抗原特異的な免疫応答を高めるための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2012525410A JP2012525410A (ja) 2012-10-22
JP2012525410A5 true JP2012525410A5 (enExample) 2013-06-20
JP5690814B2 JP5690814B2 (ja) 2015-03-25

Family

ID=43050757

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012508648A Expired - Fee Related JP5690814B2 (ja) 2009-04-28 2010-04-28 抗原特異的な免疫応答を高めるための組成物及び方法
JP2014193613A Withdrawn JP2015017117A (ja) 2009-04-28 2014-09-24 抗原特異的な免疫応答を高めるための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014193613A Withdrawn JP2015017117A (ja) 2009-04-28 2014-09-24 抗原特異的な免疫応答を高めるための組成物及び方法

Country Status (7)

Country Link
US (1) US20120244173A1 (enExample)
EP (1) EP2424990A4 (enExample)
JP (2) JP5690814B2 (enExample)
AU (1) AU2010246273B2 (enExample)
BR (1) BRPI1011902A2 (enExample)
CA (1) CA2760310A1 (enExample)
WO (1) WO2010129339A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
WO2004098526A2 (en) 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
EP3269387B1 (en) * 2012-01-24 2019-07-17 Sanford Health Polynucleotides and polypeptides for treating oncogenic viral polypeptide positive tumors
WO2014127478A1 (en) 2013-02-21 2014-08-28 Children's Hospital Of Eastern Ontario Research Institute Inc. Vaccine composition
EP3013364B1 (en) 2013-06-25 2022-08-03 International AIDS Vaccine Initiative, Inc. Tuberculosis compositions and methods of using the same
AU2015204503B2 (en) 2014-01-13 2020-07-09 Baylor Research Institute Novel vaccines against HPV and HPV-related diseases
WO2016025295A1 (en) * 2014-08-06 2016-02-18 The Johns Hopkins University Compositions and methods for enhancing antigen-specific immune responses
WO2017218867A1 (en) 2016-06-16 2017-12-21 Aeras Tuberculosis compositions and methods of treating or preventing tuberculosis
AU2018299884A1 (en) * 2017-07-10 2019-12-19 Dana-Farber Cancer Institute, Inc. Identification and use of cytotoxic T lymphocyte (CTL) antigen-specific target cell killing enhancer agents
JP2022512593A (ja) * 2018-10-04 2022-02-07 スクイーズ バイオテクノロジーズ カンパニー 抗原提示細胞の機能を増強するための生体分子の細胞内送達
EP3897846A1 (en) * 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Methods of inducing an immune response
US20230031287A1 (en) * 2019-12-13 2023-02-02 Northwestern University Method and composition for enhancing the immune response

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE910909A1 (en) * 1990-03-20 1991-09-25 Behringwerke Ag Seroreactive epitopes of human Papillomavirus (HPV) 16¹proteins
US20040106128A1 (en) * 2002-06-27 2004-06-03 Majumdar Anish Sen Cancer vaccines containing xenogeneic epitopes of telomerase reverse transcriptase
WO2006120474A2 (en) * 2005-05-13 2006-11-16 Oxxon Therapeutics Ltd Compositions for inducing an immune response against tumor antigens
CA2634377A1 (en) * 2005-12-21 2007-06-28 Glaxo Group Limited Method of eliciting immune response
US20110129489A1 (en) * 2007-07-06 2011-06-02 Erik Depla Methods for generating an immune response using dna and a viral vector

Similar Documents

Publication Publication Date Title
JP2012525410A5 (enExample)
US20240002449A1 (en) Respiratory syncytial virus (rsv) vaccine
US10925946B2 (en) Vaccination methods
EP2958994B1 (en) Vaccine composition
JP2019526580A5 (enExample)
JP2012501959A5 (enExample)
FI2970398T3 (fi) Rsv f -prefuusioproteiineja ja niiden käyttö
JP2016128513A5 (enExample)
JP2016513115A5 (enExample)
CN106459998A (zh) 预防或治疗慢性乙型肝炎病毒(hbv)感染的基于病毒样囊泡(vlv)的疫苗
Bivas-Benita et al. Airway CD8+ T cells induced by pulmonary DNA immunization mediate protective anti-viral immunity
Smith et al. The development of prophylactic and therapeutic EBV vaccines
WO2006037038B1 (en) Optimized vaccines to provide protection against ebola and other viruses
JP2013545448A5 (enExample)
WO2014063601A1 (zh) 诱导肿瘤特异性免疫的疫苗及其应用
JPWO2021163438A5 (enExample)
Zhao et al. Cross-protection against homo and heterologous influenza viruses via intranasal administration of an HA chimeric multiepitope nanoparticle vaccine
Geng et al. Amiloride enhances antigen specific CTL by faciliting HBV DNA vaccine entry into cells
CN102000330B (zh) 一种核酸疫苗佐剂及其构建方法
WO2002078732A1 (en) A noval vaccine formulation consisting of dna vaccine inactivated virus
CN102038951B (zh) 基于mcp-1设计的核酸疫苗佐剂及其构建方法
Nosaka et al. Next Generation RNA/Protein‐Carrying Vector With Pleiotropic Activity
CN114031675A (zh) 基于SARS-CoV-2的S蛋白的疫苗和组合物
US20250295759A1 (en) Method for enhancing immunity
JP7454320B2 (ja) アジュバントとしての腫瘍溶解性ウイルス